Compare ACA & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACA | IBRX |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.1B |
| IPO Year | 2018 | 2015 |
| Metric | ACA | IBRX |
|---|---|---|
| Price | $127.10 | $9.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $117.50 | $12.60 |
| AVG Volume (30 Days) | 186.1K | ★ 31.3M |
| Earning Date | 05-28-2026 | 05-18-2026 |
| Dividend Yield | ★ 0.16% | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ 3.18 | N/A |
| Revenue | ★ $2,569,900,000.00 | $113,288,000.00 |
| Revenue This Year | $13.27 | $93.25 |
| Revenue Next Year | $5.43 | $149.39 |
| P/E Ratio | $39.83 | ★ N/A |
| Revenue Growth | 11.35 | ★ 668.31 |
| 52 Week Low | $68.11 | $1.83 |
| 52 Week High | $131.00 | $12.43 |
| Indicator | ACA | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 62.98 | 64.58 |
| Support Level | $91.77 | $2.23 |
| Resistance Level | $131.00 | N/A |
| Average True Range (ATR) | 3.80 | 1.25 |
| MACD | -0.26 | 0.22 |
| Stochastic Oscillator | 59.14 | 55.85 |
Arcosa Inc is a manufacturer and producer of infrastructure-related products and services. It operates in three segments: Construction Products, Engineered Structures, and Transportation Products. The Construction Products segment produces and sells construction aggregates and manufactures and sells trench shields and shoring products and services for infrastructure-related projects. The Transportation Products segment manufactures and sells products for the inland waterway and rail transportation industries. The Engineered Structures segment manufactures and sells products for energy-related businesses, including structural wind towers, telecommunication structures, steel utility structures for electricity transmission and distribution, and storage and distribution containers.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.